Eurofins expands its clinical diagnostic footprint with the acquisition of VRL Laboratories

02-Sep-2016 - Netherlands

Eurofins Scientific announces the acquisition of VRL Laboratories, a laboratory focusing on pre-transplant testing for the eligibility determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) in the US.

Founded in 2010, VRL has become a reference laboratory solely focused on donor eligibility testing and microbiology testing for the transplant and medical communities. The company offers a broad menu of infectious disease screening assays to support the FDA’s21 CFR 1271 donor eligibility determination testing requirements, specifically for eye, tissue, organ, stem cell and cord blood, as well as reproductive tissues. VRL employs a total of 60 staff across its main facility, and its satellite laboratories.

The acquisition of VRL reinforces Eurofins’ footprint in specialty clinical testing services and consolidates the Group’s leadership in the transplantation testing market. Furthermore, VRL’s microbiology testing services expands Eurofins’ testing portfolio and increases client penetration in the transplantation testing market. In return, VRL will have access to the Group’s clients and competencies, as well as its laboratory network infrastructure, which should support its further development.   

Comment from Dr. Gilles Martin, Eurofins CEO: “The acquisition of VRL is another demonstration of our strategy of expanding and strengthening our network of competence centers. In combination with ViraCor and Diatherix, VRL reinforces the Group’s footprint in the testing market for transplantation and infectious diseases.” 

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances